This project examines the accounting of research and development projects and other intangible assets under IASB International Financial Reporting Standard (IFRS). The project will analyze two companies one Danish, Novo Nordisk and German, Boehringer Ingelheim, assessment of the disclosure requirements in the standards IAS 38 and IAS 36 in the period 2016 to 2017. The projects assess the following research question: “Thus, Novo Nordisk and Boehringer Ingelheim report after current international standards from IFRS about research and development projects, so the users of the annual report understand the costs tied to these projects” The first section of the project comprises a description of the methods applied to maintain a high quality and validity of data throughout the assignment and the methods which is applied to collect data and select a unit for analysis. Consecutive, there will be a description and discussion of the accounting theory of the financial report, IFRS, research and development projects and intangible assets that are conducted, with relevant references to Novo Nordisk and Boehringer Ingelheim’s annual report from 2017 and the comparability year 2016. Subsequent, the IFRS standards IAS 38 and IAS 36 are examined with following references to both company’s annual reports. The research and development and other intangible assets that are described in the project are prescribed under the international standard IAS 38. IAS 36 is the standard for amortization and impairment of assets and is substantial in the accounting for research and development projects and other intangible assets. These assets which can have infinite life in the annual report, are not amortized, but are instead required to be tested for impairment annually. The conclusion demonstrates that there have been no major discrepancies in the company’s assessment of the disclosure requirements in the standards IAS 38 and IAS 36 in the period 2016 to 2017. However, the analysis shows minor discrepancies in IAS 36.126 for both companies, but the discrepancies are not identical. Which leads to that the alignment of the two companies are also considering and here it can be conducted that there are some differences when it comes to the reporting of the costs associated with research and development projects. Following the conclusion, the project will comprise a discussion, in which the subsequent presentation of research and development projects in the annual report will be taking into account along with alterations to the current report standards from the companies.
|Educations||Graduate Diploma in Accounting and Financial Management, (Diploma Programme) Final Thesis|
|Number of pages||86|